The drugs have become popular for their significant weight-loss effects, but their high cost has made them inaccessible for many.

Ozempic (semaglutide) is a powerful and versatile drug, offering dual benefits: controlling blood sugar in type 2 diabetes, and facilitating weight loss as a secondary effect. While its primary ...

Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

Novo Nordisk offers Wegovy and Ozempic at $199/month for new self-pay patients, valid for the first two months until March 31, 2026. The promotion aligns with a national agreement to improve access ...

Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling ...

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly ...

Eli Lilly reduced Zepbound vial prices for self-paying patients via LillyDirect, aiming to lower obesity treatment costs and ...